Amgen (AMGN) – Investment Analysts’ Weekly Ratings Updates

Amgen (NASDAQ: AMGN) recently received a number of ratings updates from brokerages and research firms:

  • 2/5/2018 – Amgen was downgraded by analysts at Atlantic Securities from an “overweight” rating to a “neutral” rating. They now have a $187.01 price target on the stock.
  • 2/4/2018 – Amgen had its “hold” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $191.00 price target on the stock. They wrote, “AMGN’s top-line continues to be uninspiring, but the bottom line will meaningfully benefit from a lower than expected tax rate (surprise, surprise) and a large, accelerated $10B share buyback. There are several moving pieces to consider heading into 2018 (which are apparent in management’s uncharacteristically wide guidance range), including timing/magnitude of legacy franchise erosion (e.g., Neulasta & Sensipar), trajectory of recent/upcoming launches (e.g., Kyprolis, Repatha, Aimovig), and the extent to which AMGN chooses to exercise its upsized share repurchase authorization (now ~$14B in total). While we continue to be keenly interested in potential for M&A (which AMGN continues to be constructive on) and the earlier stage pipeline, we maintain our Neutral rating pending evidence of sustainable near-/mid-term growth.””
  • 2/2/2018 – Amgen had its “market perform” rating reaffirmed by analysts at Leerink Swann.
  • 2/2/2018 – Amgen had its “buy” rating reaffirmed by analysts at Cowen Inc. They now have a $204.00 price target on the stock.
  • 2/2/2018 – Amgen had its price target raised by analysts at Credit Suisse Group AG from $191.00 to $194.00. They now have a “neutral” rating on the stock.
  • 2/2/2018 – Amgen had its price target raised by analysts at BMO Capital Markets from $192.00 to $202.00. They now have a “market perform” rating on the stock.
  • 2/2/2018 – Amgen had its price target lowered by analysts at Morgan Stanley from $204.00 to $196.00. They now have an “overweight” rating on the stock.
  • 2/2/2018 – Amgen had its price target lowered by analysts at Piper Jaffray Companies from $194.00 to $190.00. They now have an “overweight” rating on the stock.
  • 2/1/2018 – Amgen had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $192.00 price target on the stock. They wrote, “We expect Q4 ’17 trends for both unit demand and net selling price to continue into 2018 – Expect Q1 ’18 sales to be ~ 20% of full year 2018 sales Neulasta US = 969 / 950 / 949 Neulasta Ex-US = 145 / 151 / 152 Neulasta WW = 1114/ 1103 / 1100 Neupogen US = 82 / 87 / 87 PLEASE REFER TO PAGE 5 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.””
  • 1/30/2018 – Amgen had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $205.00 price target on the stock.
  • 1/24/2018 – Amgen had its price target raised by analysts at JPMorgan Chase & Co. from $184.00 to $189.00. They now have a “neutral” rating on the stock.
  • 1/24/2018 – Amgen had its “hold” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $189.00 price target on the stock.
  • 1/23/2018 – Amgen was upgraded by analysts at Argus from a “hold” rating to a “buy” rating. They now have a $220.00 price target on the stock, up previously from $192.33.
  • 1/18/2018 – Amgen was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 1/5/2018 – Amgen was given a new $205.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 1/3/2018 – Amgen was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $184.25 price target on the stock.
  • 1/2/2018 – Amgen had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies.
  • 12/28/2017 – Amgen was given a new $192.00 price target on by analysts at Mizuho. They now have a “buy” rating on the stock.
  • 12/22/2017 – Amgen was given a new $192.00 price target on by analysts at Mizuho. They now have a “buy” rating on the stock.
  • 12/18/2017 – Amgen was downgraded by analysts at Citigroup Inc to a “neutral” rating.
  • 12/15/2017 – Amgen was downgraded by analysts at Goldman Sachs Group Inc from a “conviction-buy” rating to a “buy” rating.

Amgen, Inc. (NASDAQ:AMGN) opened at $173.46 on Monday. Amgen, Inc. has a 52-week low of $152.16 and a 52-week high of $201.23. The company has a market capitalization of $125,121.81, a price-to-earnings ratio of 67.49, a PEG ratio of 2.13 and a beta of 1.42. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the consensus estimate of $3.03 by ($0.14). Amgen had a return on equity of 30.87% and a net margin of 8.66%. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.84 billion. During the same quarter in the prior year, the business earned $2.89 earnings per share. The company’s quarterly revenue was down 2.7% on a year-over-year basis. equities research analysts predict that Amgen, Inc. will post 13.22 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be given a dividend of $1.32 per share. This is a positive change from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 annualized dividend and a dividend yield of 3.04%. The ex-dividend date is Wednesday, February 14th. Amgen’s dividend payout ratio (DPR) is currently 178.99%.

In other news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total value of $283,070.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.19% of the company’s stock.

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Receive News & Ratings for Amgen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply